Boey Authorized in Canada: What Clients Should Know

What Authorization Means for Your Timing

If you are seeing headlines about Boey and wondering what “authorized in Canada” actually means for you, start with the paperwork. Health Canada’s Notice of Compliance (NOC) record for BOEY lists an NOC date of 2026-06-22, and the Drug Product Database lists BOEY as “Marketed” with an original market date of 2026-10-05.

For clients across Toronto, Vaughan, and the GTA, the practical question is less about buzz and more about planning. Authorization matters, but it does not make your onset, look, or timing identical to anyone else’s. Your assessment, your facial movement, and your plan for events still matter.

This article explains what Health Canada authorization can tell you, the role of the product monograph, and how to think about shorter duration patterns and event timing without assuming everyone responds the same way.

What Authorized in Canada Means

When a prescription product is authorized for sale in Canada, it has gone through Health Canada’s review under the Food and Drugs Act and its Regulations, which regulate the safety, efficacy and quality of drugs and medical devices. Health Canada also conducts post market surveillance on marketed health products.

In practical terms, authorization gives you a Canadian regulatory record to check, plus a defined label and product monograph to read. Health Canada’s Drug Product Database is intended for finding drugs authorized for sale by Health Canada, and it includes product monographs for human drugs.

What Health Canada Records Show for BOEY

Health Canada’s Notice of Compliance Information entry for BOEY lists the medicinal ingredient as “TRENIBOTULINUMTOXINE,” the strength as “1400 UNIT/VIAL,” the route as “Intramuscular,” and the product type as a “Prescription Pharmaceutical.” It also lists the NOC date as 2026-06-22 and indicates “NOC with conditions: No.”

Health Canada’s Drug Product Database product information page for BOEY lists its current status as “Marketed,” with a current status date of 2026-10-05 and an original market date of 2026-10-05, and it links a product monograph PDF with a listed date of 2026-06-22.

What Authorization Does and Does Not Guarantee

It helps to treat authorization as a strong baseline for accountability, not as a promise about your personal result. The product monograph is the formal document that describes the product, and it matters for informed consent because it sets expectations and warnings in a standardized format.

Results and Timelines Still Vary

The PrBOEY® product monograph explicitly warns that “frequencies of adverse reactions observed in the clinical trials may not reflect frequencies observed in clinical practice.” That same idea applies to the broader experience: controlled trials and real life do not behave identically, and individual response factors still show up in practice.

Another important limit is that authorization is indication specific. In other words, a product’s authorized use is defined, not open ended. For any person in Ontario, whether a specific aesthetic goal is appropriate still sits inside professional assessment, consent, and scope of practice requirements.

Approval Outside Canada Does Not Carry Into Ontario

The College of Nurses of Ontario (CNO) practice guideline for aesthetic services is clear about jurisdiction. It states: “Approval of a product outside of Canada, for example, by the United States Food and Drug Administration (FDA), does not extend to Ontario.”

If you are choosing a clinic, this point matters because it pushes the conversation back to Canadian authorization and Ontario standards. A careful injector should be able to name the exact product used, including the brand, as part of consent.

Boey Basics You Can Verify

Boey is a prescription pharmaceutical, and the most reliable consumer facing facts come from the Canadian regulatory record and the Canadian product monograph.

What the AbbVie Monograph Calls BOEY

In the AbbVie Canada monograph, the brand is listed as “PrBOEY®.” The proper name is “TrenibotulinumtoxinE for Injection,” described as “Clostridium botulinum serotype E neurotoxin.” The dosage form is listed as “Lyophilized powder for solution for injection,” for “Intramuscular use,” at “1400 Units per single-use vial.” The same document shows “Date of Authorization: 2026-06-30” and “Control Number: 300062.”

Non Medicinal Ingredients Listed

The monograph’s composition table lists these non medicinal ingredients: “L-Histidine, L-Histidine Hydrochloride Monohydrate, L-Methionine, Poloxamer 188, Sodium Chloride, Trehalose Dihydrate.” If you have a history of sensitivities, bring that up during your consultation so it can be considered as part of appropriateness and consent.

Shorter Duration Patterns and Who May Like Them

Clients often ask one practical thing: “How long will I be committed to this look?” For trenibotulinumtoxinE, the peer reviewed Phase 3 literature retrieved describes rapid results with a short duration of effect in the context of glabellar lines studies.

What the Phase 3 Literature Highlights

A PubMed record for a pivotal Phase 3 study concludes: “TrenibotE was well tolerated and improved GL severity with rapid results and short duration of effect.” An Aesthetic Surgery Journal advance article page describes trenibotE as rapidly improving glabellar line severity, detected as early as “Hour 8,” and describes a shorter duration of clinical effect compared with BoNT/A products. This is study context, separate from Canadian labeling.

Where a Shorter Commitment Can Be Useful

People who feel toxin hesitant sometimes want a clearer exit door. The Aesthetic Surgery Journal page explicitly mentions “utility as a trial toxin for toxin-hesitant patients,” which is a non obvious planning advantage: a shorter duration experience can make it easier to learn your preferences about brow heaviness, expression, and how you like your face to move without feeling locked in for months.

A shorter duration pattern may also appeal if you want facial movement to return sooner during a specific period, or if you prefer more frequent fine tuning. Those are preference based reasons, and they still require an individualized plan.

How to Plan for Events Without Guessing

Event timing is where good decision making matters most, because the stakes feel higher and you can feel pressured to pick a date with confidence. The safest way to plan is to build in buffer for settling time and for short lived injection associated effects.

What the Monograph Says About Injection Associated Effects

The PrBOEY® monograph states: “As is expected for any injection procedure, localized pain, inflammation, paresthesia, hypoesthesia, tenderness, swelling/oedema, erythema, localized infection, bleeding and/or bruising may be associated with the injection.” In the glabellar line clinical trials described in the monograph, “Onset was generally within the first week. In most cases, the events resolved in 2 to 8 days rarely lasting longer.”

This gives you a concrete planning anchor for short term visible effects like swelling or bruising, while still respecting that “generally” and “in most cases” means some people will not follow an identical timeline.

A Practical, Consultation First Approach

If you have a must look good date, plan your consult early enough that you can map out assessment, treatment, settling time, and any follow up your injector anticipates. For anyone new to neuromodulators, consider a trial run well in advance of the event so your injector can see how your face responds. The “trial toxin” idea is consistent with the published literature framing for BoNT/E in glabellar lines studies.

Repeat clients can use their own history as a guide, but each session can still vary. Changes in dose and placement, muscle condition, and anatomy can change how the result reads on your face.

Why One Person’s Result Is Not Your Timeline

Two people can be treated for the same concern and experience different effect patterns. Variability is not a footnote, it is a central part of safe expectation setting.

Technique and Diffusion Matter

The PrBOEY® monograph states: “Local muscle weakness represents the expected pharmacological action of botulinum toxin in muscle tissue. However, weakness of adjacent muscles associated with local diffusion and/or injection technique has been reported.” For a client, this is the clearest reason to choose a provider who assesses movement carefully and treats with an anatomy first plan.

Anatomy and Altered Anatomy Matter

The same monograph states that the injector “should be familiar with the relevant anatomy and any alterations to the anatomy due to prior surgical procedures.” This point is easy to miss as a consumer, but it changes how you should book: bring up prior surgery or significant prior aesthetic work during assessment, because it affects planning.

Serious Symptoms Need Prompt Attention

The monograph also warns that progressive signs or symptoms of muscular weakness remote to the site of injection may include “ptosis and diplopia,” and it references other serious adverse effects including swallowing and speech disorders. These are not the typical experience, but they are part of informed consent for botulinum toxin products.

What Ontario Standards Require From Your Provider

In Ontario, safety and ethics are not only about product choice. They are also about how the service is assessed, authorized, and consented.

Assessment and Appropriateness

The College of Nurses of Ontario states that aesthetic services “carry the same risks for clients as do medical procedures,” and nurses must practice within scope and comply with standards and legislation. The CNO practice guideline also states that appropriateness is based on an assessment that evaluates the client’s health history, contraindications, physical assessment and the best evidence available.

Informed Consent Should Be Specific

CNO’s guidance for informed consent includes communicating the procedure’s expected results and potential follow up needs, risks and complications, and “the exact nature of all products used including the brand of the product.” As a client, this gives you a clear standard for what your injector should be able to explain in plain language before any treatment is performed.

Questions Worth Asking at Your Consult

For a product that is new to you, the best consumer protection is a consultation that is structured, specific, and easy to understand. If you are booking for frown line concerns or considering a shorter duration neurotoxin pattern, start the conversation in a way that surfaces timing and risk early.

• Which brand will be used, and what is it authorized for in Canada?
• What short term injection associated effects should I plan for, including bruising or swelling?
• What would follow up look like for me, based on my facial movement and goals?
• What symptoms would mean I should contact the clinic promptly?

If you are exploring neuromodulators as part of a bigger plan for balance, ask how this fits into full face planning rather than treating one line in isolation. A facial harmony approach is often where outcomes look the most refined, because the goal stays tied to your proportions and expression.

Boey’s Canadian authorization gives you a clear regulatory record to verify and a product monograph to anchor informed consent. Your outcome still depends on personal factors and on how carefully you are assessed and treated.

If you want to discuss neuromodulators for facial lines and timing around an event, start with an assessment centered on movement and facial balance through Full face Botox.